Blood Res.  2024;59:14. 10.1007/s44313-024-00014-w.

Transfusion‑transmitted infections

• Kim H
• Ko D

• KMID: 2562518
• DOI: http://doi.org/10.1007/s44313-024-00014-w

Abstract

The risk of transfusion-transmitted infection (TTI) has always existed because transfused blood products are biologi‑ cal materials derived from humans. To prevent TTIs, screening strategies have been developed for various infectious diseases, such as hepatitis B virus, hepatitis C virus, and human immunodeficiency virus, contributing significantly to reducing TTI globally. Nevertheless, septic transfusion reactions (STRs) due to bacterial contamination remain an unresolved issue. Various infectious diseases can be transmitted through blood products, and preventive and selective screening strategies have been applied across different regions. Although multiple strategies, includ‑ ing culture-based and rapid detection kit-based methods, have been introduced to overcome STRs, complete preven‑ tion has not yet been achieved. Recently, pathogen inactivation methods have been developed to eliminate nonspecific organisms rather than screening specific organisms. This approach is anticipated to contribute significantly to diminishing the risk of TTIs in the future.

Keyword

Transfusion-transmitted infection; Hepatitis B virus; Hepatitis C virus; Human immunodeficiency virus; Pathogen inactivation

Reference

1. Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. 1983; Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 220:868–71. DOI: 10.1126/science.6189183. PMID: 6189183.

2. CfD C. 1982; Pneumocystis carinii pneumonia among persons with hemophilia A. MMWR Morb Mortal Wkly Rep. 31:365–7.

3. Gjerset GF, McGrady G, Counts RB, Martin PJ, Jason J, Kennedy S, et al. 1985; Lymphadenopathy-associated virus antibodies and T cells in hemophiliacs treated with cryoprecipitate or concentrate. Blood. 66:718–20. DOI: 10.1182/blood.V66.3.718.718. PMID: 2992642.

4. Cohn C, Delaney M, Johnson ST, Katz LM, Schwartz J. 2023. Technical Manual. 21st ed. AABB;Bethesda: DOI: 10.6028/nist.tn.2225r1.

5. Kang JW, Shin S, Seo DH, Kang J, Ko DH, Song CE, et al. 2019; Estimation of the residual risk of transfusion-transmissible infectious agents in Korea. Korean J Blood Transfus. 30:156–62. DOI: 10.17945/kjbt.2019.30.2.156.

6. Blumberg BS. 1964; Polymorphisms of the serum proteins and the development of iso-preciptins in transfused patients. Bull N Y Acad Med. 40:377. PMID: 14146804. PMCID: PMC1750599.

7. Candotti D, Allain JP. 2009; Transfusion-transmitted hepatitis B virus infection. J Hepatol. 51:798–809. DOI: 10.1016/j.jhep.2009.05.020. PMID: 19615780.

8. Dodd RY, Crowder LA, Haynes JM, Notari EP, Stramer SL, Steele WR. 2020; Screening blood donors for HIV, HCV, and HBV at the American Red Cross: 10-year trends in prevalence, incidence, and residual risk, 2007 to 2016. Transfus Med Rev. 34:81–93. DOI: 10.1016/j.tmrv.2020.02.001. PMID: 32178888.

9. Grady GF, Chalmers TC, Group BI-HL. 1964; Risk of post-transfusion viral hepatitis. N Engl J Med. 271:337–42. DOI: 10.1056/NEJM196408132710702. PMID: 14171801.

10. van der Poel CL. 1999; Hepatitis C virus and blood transfusion: past and present risks. J Hepatol. 31:101–6. DOI: 10.1016/S0168-8278(99)80384-5. PMID: 10622570.

11. Chozie NA, Satiti MA, Sjarif DR, Oswari H, Ritchie NK. 2022; The impact of nucleic acid testing as a blood donor screening method in transfusion-associated hepatitis C among children with bleeding disorders in Indonesia: a single-center experience. Blood Res. 57:129–34. DOI: 10.5045/br.2022.2021219. PMID: 35620907. PMCID: PMC9242827.

12. Seo DH, Whang DH. 2009; The usefulness of the alanine aminotransferase test for blood donors. Korean J Blood Transf. 20:159–66.

13. Colpitts TM, Conway MJ, Montgomery RR, Fikrig E. 2012; West Nile Virus: biology, transmission, and human infection. Clin Microbiol Rev. 25:635–48. DOI: 10.1128/CMR.00045-12. PMID: 23034323. PMCID: PMC3485754.

14. Pisani G, Cristiano K, Pupella S, Liumbruno GM. 2016; West Nile virus in Europe and safety of blood transfusion. Transfus Med Hemother. 43:158–67. DOI: 10.1159/000446219. PMID: 27403087. PMCID: PMC4924479.

15. Magnus MM, Espósito DLA, Costa VAD, Melo PS, Costa-Lima C, Fonseca BALD, et al. 2018; Risk of Zika virus transmission by blood donations in Brazil. Hematol Transfus Cell Ther. 40:250–4. DOI: 10.1016/j.htct.2018.01.011. PMID: 30128434. PMCID: PMC6098187.

16. Aubry M, Richard V, Green J, Broult J, Musso D. 2016; Inactivation of Zika virus in plasma with amotosalen and ultraviolet A illumination. Transfusion. 56:33–40. DOI: 10.1111/trf.13271. PMID: 26283013.

17. Youn KW, Kang JW, Kwon SY, Oh DJ. 2015; Consideration of the improvement of the confirmatory assay for the anti-HTLV positive blood donation. Korean J Blood Transfus. 26:300–8. DOI: 10.17945/kjbt.2015.26.3.300.

18. Lee CK, Wong HK, Ho PL, Tsoi WC, Lee KY, Tsui GT, et al. 2012; Significant bacterial contamination risk reduction with the use of diversion pouch. Transfus Med. 22:404–8. DOI: 10.1111/j.1365-3148.2012.01194.x. PMID: 23036088.

19. Levy JH, Neal MD, Herman JH. 2018; Bacterial contamination of platelets for transfusion: strategies for prevention. Crit Care. 22:271. DOI: 10.1186/s13054-018-2212-9. PMID: 30367640. PMCID: PMC6204059. PMID: a849b1c2196f4d8b964576b496d823c4.

20. Lin L, Cook DN, Wiesehahn GP, Alfonso R, Behrman B, Cimino GD, et al. 1997; Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion. 37:423–35. DOI: 10.1046/j.1537-2995.1997.37497265344.x. PMID: 9111281.

21. Williamson LM, Cardigan R, Prowse CV. 2003; Methylene blue-treated freshfrozen plasma: what is its contribution to blood safety? Transfusion. 43:1322–9. DOI: 10.1046/j.1537-2995.2003.00483.x. PMID: 12919437.

22. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, et al. 2004; Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood. 104:1534–41. DOI: 10.1182/blood-2003-12-4443. PMID: 15138160.

23. Burnouf T, Tseng YH, Kuo YP, Su CY. 2008; Solvent/detergent treatment of platelet concentrates enhances the release of growth factors. Transfusion. 48:1090–8. DOI: 10.1111/j.1537-2995.2008.01691.x. PMID: 18373502.

24. Bell CE, Botteman MF, Gao X, Weissfeld JL, Postma MJ, Pashos CL, et al. 2003; Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin Ther. 25:2464–86. DOI: 10.1016/S0149-2918(03)80288-6. PMID: 14604745. PMCID: PMC7133650.

25. Janssen MP, van der Poel CL, Buskens E, Bonneux L, Bonsel GJ, van Hout BA. 2006; Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands. Transfusion. 46:956–65. DOI: 10.1111/j.1537-2995.2006.00828.x. PMID: 16734812.

26. Moeremans K, Warie H, Annemans L. 2006; Assessment of the economic value of the INTERCEPT blood system in Belgium. Transfus Med. 16:17–30. DOI: 10.1111/j.1365-3148.2006.00644.x. PMID: 16480436.